Singapore REITs Monthly: Negatives Largely Priced In with Selective Overweight Stance May 19, 2026

Singapore REITs Monthly: Negatives Largely Priced In with Selective Overweight Stance

Market Performance and Sector Overview

Singapore REITs (S-REITs) faced continued headwinds in March 2026, with the S-REITs Index declining 6.9% following a 1.9% drop in February. Despite the broader market weakness, Suntec REIT emerged as the sole positive performer, gaining 2.8% after completing the acquisition of its REIT manager by Acrophyte Asset Management. At the other end of the spectrum, KORE US REIT suffered the steepest decline of 17.7% as it resumed dividends in the second half of 2025 with approximately 10% payout.

Sector performance varied significantly, with healthcare REITs demonstrating relative resilience by declining only 0.7%, whilst overseas commercial properties bore the brunt of selling pressure, falling 12.9%. The S-REITs Index now trades at a forward dividend yield spread of approximately 3.8% and a price-to-net asset value of 0.9x, representing -1.1 standard deviations below the mean.


Valuation Assessment and Market Outlook

Current valuations appear to have largely incorporated downside risks stemming from Middle East conflicts, which have contributed to more hawkish interest rate expectations. However, the impact of higher utility costs has been broadly contained, as most expenses are either hedged or passed through to tenants, providing some operational stability.

Phillip Securities Research maintains an OVERWEIGHT recommendation on S-REITs whilst adopting a more selective approach. The firm expects approximately 3% distribution per unit growth on average for covered S-REITs in FY26e, supported by higher rents from contractual escalations and positive rental reversions, alongside lower financing costs. This outlook is underpinned by continued SORA rate declines, with 3-month SORA at approximately 1.05%, representing a 150 basis points year-on-year decrease.


Investment Strategy and Top Picks

The research house favours REITs with strong balance sheets, earnings resilience, and potential for distribution growth. Within sub-sectors, retail properties are preferred, where rental reversions are expected to remain robust in the high single-digits during 2026. Top picks include high-yielding S-REITs above 8.5% with resilient portfolios: Stoneweg Europe Stapled Trust (BUY, target price €1.89), Elite UK REIT (BUY, target price £0.41), and United Hampshire US REIT (BUY, target price US$0.69). Prime US REIT (BUY, target price US$0.32) is also favoured for its attractive valuation at 0.34x price-to-net asset value and cash flow visibility.


Frequently Asked Questions

Q: How did Singapore REITs perform in March 2026?

A: The S-REITs Index fell 6.9% in March 2026, extending the 1.9% decline from February. Only Suntec REIT posted gains of 2.8%, whilst KORE US REIT was the worst performer, declining 17.7%.

Q: What is Phillip Securities Research's recommendation on Singapore REITs?

A: Phillip Securities Research maintains an OVERWEIGHT recommendation on S-REITs but adopts a more selective approach, favouring names with strong balance sheets, earnings resilience, and potential for distribution growth.

Q: What are the current valuation levels for Singapore REITs?

A: The S-REITs Index trades at a forward dividend yield spread of approximately 3.8% and a price-to-net asset value of 0.9x, which is -1.1 standard deviations below the mean.

Q: What growth expectations does the research house have for FY26e?

A: Phillip Securities Research expects approximately 3% distribution per unit growth on average for covered S-REITs in FY26e, supported by higher rents and lower financing costs from declining SORA rates.

Q: Which sub-sector does the research house prefer and why?

A: The firm prefers retail properties, where rental reversions are expected to remain robust in the high single-digits during 2026.

Q: What are the top stock picks mentioned in the report?

A: Top picks include Stoneweg Europe Stapled Trust (BUY, €1.89), Elite UK REIT (BUY, £0.41), United Hampshire US REIT (BUY, US$0.69), and Prime US REIT (BUY, US$0.32).

Q: How have equity fund raises for acquisitions performed historically?

A: Data from 2025-2026 shows mixed market reactions to equity fund raises, with performance highly dependent on the accretive nature of deals. The market demonstrated clear discipline regarding deal quality, with dilutive transactions suffering sharper sell-offs.

Q: What factors support the current investment thesis?

A: S-REITs' share prices are supported by global fund flows into stable, defensive strategies, with the sector viewed as a safe-haven amid market volatility and heightened geopolitical tensions.


 

This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst. 

 

Disclaimer

These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.

Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com